New perspectives in cardiovascular risk reduction: Focus on HDL;Nuove prospettive nella riduzione del rischio cardiovascolare: Focus su HDL

Monaldi Archives for Chest Disease - Cardiac Series

Volumn 80, Issue 1, 2013, Pages 27-30

  Paolillo, Stefania ^a   Della Ratta, Giuseppe Luca ^a   Vitagliano, Alice ^a   Cirillo, Annapaola ^a   Lardino, Elisabetta ^a   Formisano, Tiziana ^a   Fabiani, Irma ^a   Pellegrino, Angela Maria ^a   Riello, Pietro ^a   Perrone Filardi, Pasquale ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Cardiovascular risk; Dyslipidemia; HDL

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; DYSLIPIDEMIA; HUMAN; LIFESTYLE MODIFICATION; LIPOPROTEIN BLOOD LEVEL; PHARMACEUTICAL CARE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; PRACTICE GUIDELINE; PROTEIN BLOOD LEVEL;

EID: 84887890948     PISSN: 11220643     EISSN: None     Source Type: Journal    
DOI: 10.4081/monaldi.2013.88     Document Type: Review

References (41)

1. Roger LV, Go AS, Lloyd-Jones DM, et al. Heart Disease and Stroke Statistics - 2012 Update. A Report From the American Heart Association. Circulation 2012 125: e2-e220.
2. Smith SC, Allen J, Blair SN, et al. AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update. Circulation 2006; 113: 2363-2372.
3. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non -ST-Elevation Myocardial Infarction. Circulation 2007; 116: e148-e304.
4. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. Circulation 2004; 110: e82-e292.
5. Hamm CW, Bassand JP, Agewall S, et al.ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2011: 32: 2999-3054.
6. National Cholesterol Education Program. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation. 2002; 106: 3143-3421.
7. European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769-818.
8. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977; 62: 707-14.
9. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr, Bangdiwala S, Tyroler HA. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79: 8-15.
10. Wilson PW, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 1988; 8: 737-41.
11. von Eckardstein A, Nofer JR, Assmann G. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2001; 21: 13-27.
12. Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 2005; 96: 1221-32.
13. Mahdy Ali K, Wonnerth A, Huber K, Wojta J. Cardiovascular disease risk reduction by raising HDL cholesterol - current therapies and future opportunities. Br J Pharmacol 2012; 167: 1177-94.
14. Garner B, Waldeck AR, Witting PK, Rye KA, Stocker R. Oxidation of high density lipoproteins. II. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins AI and AII. J Biol Chem 1998; 273: 6088-95.
15. Suc I, Escargueil-Blanc I, Troly M, Salvayre R, Nègre-Salvayre A. HDL and ApoA prevent cell death of endothelial cells induced by oxidized LDL. Arterioscler Thromb Vasc Biol 1997; 17: 2158-66.
16. Baker PW, Rye KA, Gamble JR, Vadas MA, Barter PJ. Ability of reconstituted high density lipoproteins to inhibit cytokine-induced expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells. J Lipid Res 1999; 40: 345-53.
17. Tölle M, Pawlak A, Schuchardt M, et al. HDL-associated lysosphingolipids inhibit NAD(P)H oxidase-dependent monocyte chemoattractant protein-1 production. Arterioscler Thromb Vasc Biol 2008; 28: 1542-8.
18. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45: 89-118.
19. Pellegrino T, Storto G, Filardi PP, et al. Relationship between brachial artery flow-mediated dilation and coronary flow reserve in patients with peripheral artery disease. J Nucl Med 2005; 46: 1997-2002.
20. Perrone-Filardi P, Cuocolo A, Brevetti G, et al. Relation of brachial artery flow-mediated vasodilation to significant coronary artery disease in patients with peripheral arterial disease. Am J Cardiol 2005; 96: 1337-1341.
21. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-1681.
22. Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol 2005; 46: 1225-1228.
23. Javed U, Deedwania PC, Bhatt DL, et al. Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: An analysis of 65,396 hospitalizations from 344 hospital participating in Get With The Guidelines (GWTG). Am Heart J 2011; 161: 418-424.
24. Melloni C, Shah BR, Ou FS, et al. Lipid-lowering intensification and low-density lipoprotein cholesterol achievement from hospital admission to 1-year follow-up after an acute coronary syndrome event: Results from the Medications ApplIed aNd SusTAINed Over Time (MAINTAIN) registry. Am Heart J 2010; 160: 1121-1129.
25. Perrone-Filardi P, Poli A, Ambrosio G, Proto C, Chimini C, Chiariello M. Implementation of cardiovascular secondary prevention guidelines in clinical practice: a nationwide survey in Italy. Nutr Metab Cardiovasc Dis 2012; 22: 149-53.
26. Rubins HB, Robins SJ, Collins D, et al. for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341: 410-418.
27. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003; 290: 2292-2300.
28. ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1563-1574.
29. AIM-HIGH Investigators. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365: 2255-2267.
30. Sharpe P. Paradoxical decrease in serum high-density lipoprotein cholesterol with Tredaptive. Ann Clin Bioch 2011; 48: 584-5.
31. Magee G, Sharpe P. Paradoxical decrease in high-density lipoprotein cholesterol with fenofibrate: a quite common phenomenon. J Clin Pathol 2009; 62: 520-3.
32. Barter PJ, Rye KA. Cholesteryl Ester Transfer Protein (CETP) Inhibition as a Strategy to Reduce Cardiovascular Risk. J Lipid Res. 2012 May 1. [Epub ahead of print]
33. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357: 2109-2122.
34. Morehouse LA, Sugarman ED, Bourassa PA, et al. 2007. Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits. J Lipid Res 2007; 48: 1263-1272
35. Stroes ES, Kastelein JJ, Benardeau A, et al. Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin- aldosterone system in rats. Br J Pharmacol 2009; 158: 1763-1770.
36. Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010; 363: 2406-2415.
37. Kuivenhoven JA, de Grooth GJ, Kawamura H, et al. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol 2005; 95: 1085-1088.
38. Schwartz GG, Olsson AG, Ballantyne CM, et al. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J 2009; 158: 896-901.
39. Cao G, Beyer TP, Zhang Y, et al. Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure. J Lipid Res 2011; 52: 2169-2176.
40. Boettcher MF, Heinig R, Schmeck C, et al. Single dose pharmacokinetics, pharmacodynamics, tolerability and safety of BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein. Br J Clin Pharmacol 2012; 73: 210-218.
41. Besler C, Heinrich K, Rohrer L, et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest 2011; 121: 2693-2708.